Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.
Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, Kurose N, Ide M, Murakami J, Nara K, Yamamoto H, Ozawa Y, Takahashi H, Miura K, Miyauchi T, Yoshida S, Momoi A, Awano N, Ikushima S, Ohta Y, Furuta N, Fujimoto S, Kawanami H, Sakai T, Kawanami T, Fujita Y, Fukushima T, Nakamura S, Kinoshita T, Aoki S. Masaki Y, et al. Among authors: miura k. Int J Hematol. 2016 Jun;103(6):686-92. doi: 10.1007/s12185-016-1979-1. Epub 2016 Mar 18. Int J Hematol. 2016. PMID: 27084250
Assessment of prognostic factors in follicular lymphoma patients.
Kondo E, Ogura M, Kagami Y, Taji H, Miura K, Takeuchi T, Maeda S, Asakura S, Suzuki R, Nakamura S, Morishima Y. Kondo E, et al. Among authors: miura k. Int J Hematol. 2001 Apr;73(3):363-8. doi: 10.1007/BF02981963. Int J Hematol. 2001. PMID: 11345204
CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.
Maeda S, Kagami Y, Ogura M, Taji H, Suzuki R, Kondo E, Asakura S, Takeuchi T, Miura K, Ando M, Nakamura S, Ito T, Kinoshita T, Ueda R, Morishima Y. Maeda S, et al. Among authors: miura k. Int J Hematol. 2001 Aug;74(2):214-21. doi: 10.1007/BF02982008. Int J Hematol. 2001. PMID: 11594525 Clinical Trial.
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma.
Miura K, Takei K, Kobayashi S, Kiso S, Hirabayashi Y, Hojo A, Kodaira H, Yagi M, Kurita D, Kobayashi Y, Tanaka T, Iriyama N, Hatta Y, Kura Y, Yamazaki T, Sawada U, Takeuchi J. Miura K, et al. Int J Hematol. 2011 Jul;94(1):90-96. doi: 10.1007/s12185-011-0884-x. Epub 2011 Jun 23. Int J Hematol. 2011. PMID: 21695600
The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, Kodaira H, Inoue M, Takei M. Iriyama N, et al. Among authors: miura k. Int J Hematol. 2014 Oct;100(4):379-85. doi: 10.1007/s12185-014-1649-0. Epub 2014 Aug 5. Int J Hematol. 2014. PMID: 25092482 Clinical Trial.
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M. Kurita D, et al. Among authors: miura k. Int J Hematol. 2015 Jun;101(6):585-93. doi: 10.1007/s12185-015-1780-6. Epub 2015 Mar 17. Int J Hematol. 2015. PMID: 25776837
4,746 results